Alternatives to the hormone replacement therapy: Raloxifen and tibolon;Alternativen zur hormonersatztherapie: Raloxifen und tibolon

Zeitschrift fur Arztliche Fortbildung und Qualitatssicherung

Volumn 94, Issue 3, 2000, Pages 205-209

  Von Holst, Thomas ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Bone mineral density; Breast cancer; Climacteric complaints; Endometrium; Osteoporosis; Postmenopause

Indexed keywords

RALOXIFENE; TIBOLONE;

ARTICLE; BLEEDING; BONE DENSITY; BONE MINERALIZATION; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; SPINE FRACTURE;

ANTIHYPERTENSIVE AGENTS; BONE DENSITY; CLIMACTERIC; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE;

EID: 0034006364     PISSN: 14317621     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Kauffmun RF, Bryant HU (1995) Selective Estrogen Receptor Modulators. DN & P 8(9): 531-539
2. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, Draper M, Christiansen C (1997) Wirkungen von Raloxifen auf Knochendichte, Serumcholesterinkonzentrationen und Endometrium bei postmenopausalen Frauen. N Engl J Med 337: 1641-1647
3. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Gennant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glueer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated With Raloxifene. JAMA 282: 637-645
4. Cummings SR, Eckert SE, Krueger K, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of Raloxifene on risk of breast cancer in postmenopausal women. JAMA 281: 2189-2197
5. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW (1998) Effects of Raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279: 1445-1451
6. Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW (1997) Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 177: 1458-1464
7. Kloosterboer HJ (1997) Tibolone and its metabolites: pharmacology, tissue specificity and effects in animal models of tumors. Gynecol Endocrinol 11 (Suppl 1): 63-68
8. Bjarnason NH, Bjarnason K, Haarbo J, Rosenquist C, Christiansen C (1996) Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 81: 2419-2422
9. Prelevic GM, Bartram C, Wood J, Okolo S, Ginsburg J (1996) Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women. Gynecol Endocrinol 10: 413-204
10. Egarter Ch, Huber J, Leikermoser R et al. (1996) Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas 23: 55-62
11. Kloosterboer HJ et al. (1994) Effects of progestagens and Org ODI4 in in vitro and in vivo tumor models. J Steroid Biochem Molec Biol 49: 311-318
12. Ginsburg J et al. (1995) Clinical experience with tibolone (Livial) over 8 years. Maturitas 21: 71-76
13. Hammar M, Christau S, Nathorst-Boos J, Rud T, Garre K (1998) A doubleblind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynecol 105: 904-911